Top Page
CSPC Pharmaceutical Group
(1093)
CSPC Pharmaceutical Group (1093) vs. iShares MSCI Hong Kong ETF (EWH)
CSPC Pharmaceutical Group Business Overview & Revenue Model
CSPC Pharmaceutical Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.22B | 29.54B | 31.47B | 31.59B | 27.41B | 23.58B |
| Gross Profit | 18.16B | 20.67B | 22.19B | 22.73B | 20.79B | 17.67B |
| EBITDA | 6.72B | 7.18B | 8.59B | 8.85B | 7.57B | 6.80B |
| Net Income | 4.07B | 4.41B | 5.88B | 6.22B | 5.51B | 4.88B |
Balance Sheet | ||||||
| Total Assets | 46.00B | 47.23B | 50.92B | 41.77B | 42.50B | 35.65B |
| Cash, Cash Equivalents and Short-Term Investments | 10.63B | 8.25B | 13.09B | 13.87B | 13.87B | 10.47B |
| Total Debt | 495.00M | 507.33M | 706.90M | 659.28M | 115.04M | 523.95M |
| Total Liabilities | 11.14B | 11.20B | 11.26B | 11.07B | 9.37B | 7.96B |
| Stockholders Equity | 33.25B | 34.33B | 36.53B | 29.77B | 31.79B | 26.48B |
Cash Flow | ||||||
| Free Cash Flow | 1.48B | 1.86B | 2.29B | 6.62B | 4.15B | 5.91B |
| Operating Cash Flow | 6.86B | 4.53B | 4.18B | 9.23B | 5.86B | 7.67B |
| Investing Cash Flow | -4.66B | -3.86B | 607.27M | -6.80B | -637.33M | -2.60B |
| Financing Cash Flow | -3.32B | -5.25B | -2.30B | -1.90B | -2.20B | -1.65B |
CSPC Pharmaceutical Group Technical Analysis
CSPC Pharmaceutical Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$110.43B | 26.57 | 11.30% | 2.70% | -18.07% | -33.27% | |
73 Outperform | HK$233.73B | 44.46 | 16.09% | 0.97% | 8.68% | 0.82% | |
72 Outperform | HK$65.16B | 8.86 | 8.74% | 3.75% | -2.68% | -21.45% | |
63 Neutral | HK$152.94B | 33.19 | 9.79% | ― | 16.90% | 63.11% | |
61 Neutral | HK$140.68B | 109.18 | 8.41% | ― | 52.78% | ― | |
54 Neutral | HK$118.75B | 29.75 | 11.72% | 1.40% | 13.69% | 50.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
CSPC Pharmaceutical Group Corporate Events
CSPC Pharmaceutical Group has entered into a strategic collaboration and license agreement with AstraZeneca to co-develop innovative long-acting peptide medicines using CSPC’s sustained-release delivery and AI peptide discovery platforms. Under the deal, CSPC will continue advancing its existing preclinical long-acting peptide pipeline, discover and develop additional long-acting peptide products for AstraZeneca, and license AstraZeneca exclusive rights outside mainland China, Hong Kong, Macau and Taiwan to its once-monthly injectable weight-management portfolio, including SYH2082 and three preclinical obesity-related programmes, plus four new collaborative programmes. In return, CSPC will receive an upfront payment of US$1.2 billion, be eligible for up to US$3.5 billion in R&D milestones and up to US$13.8 billion in sales milestones, along with up to double-digit royalties on net sales, significantly strengthening its financial resources while positioning the company as a key regional partner in the fast-growing global market for long-acting obesity and weight-management drugs.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials for SYS6055 Injection, the first in vivo CAR-T therapy cleared for clinical testing in the country. The investigational product uses lentiviral vectors to generate CD19-targeting CAR-T cells directly inside the body, aiming to improve cost, accessibility and treatment speed compared with traditional ex vivo CAR-T therapies. Preclinical data show significant tumor inhibition, a favorable safety profile and time and cost benefits, and the initial approved indication is relapsed or refractory aggressive B-cell lymphoma. The company also sees potential to expand SYS6055 into other CD19-positive B-cell malignancies and autoimmune diseases, positioning CSPC at the forefront of China’s cell therapy innovation and potentially broadening its future oncology and immunology franchise.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has granted 46,462,500 restricted shares, equivalent to about 0.4% of its issued share capital, to 727 selected employees under its restricted share award scheme at nil consideration. The shares will vest in three equal tranches between January 2027 and January 2029, subject to individual performance targets over three consecutive financial years and a clawback mechanism tied to misconduct or regulatory breaches, underscoring the company’s use of equity incentives to retain and motivate staff while leaving 61,575,868 shares available for future grants under the scheme.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Innovation Pharmaceutical Co., a subsidiary of CSPC Pharmaceutical Group, has issued an early earnings indication for 2025 showing it expects to swing from profit to a significant net loss, with net profit attributable to shareholders projected to fall by 416% to 575% year-on-year and turn negative. The company attributed the deterioration in results to sharply higher research and development spending as it accelerates its innovation pipeline, reporting substantial progress including first-time clinical trial approvals for four antibody drugs, six ADC products and one mRNA vaccine, a new indication approval for its Omalizumab injection, acceptance of a marketing application for Pertuzumab injection, and advancement of two ADC candidates into Phase III trials, developments that may weigh on near-term earnings but strengthen its longer-term competitive position in innovative therapeutics.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has received approval from the U.S. Food and Drug Administration to begin clinical trials of its Class 1 innovative drug SYH2072, a highly selective aldosterone synthase inhibitor tablet for uncontrolled and resistant hypertension, complementing an earlier clinical trial approval obtained in China. Backed by positive pre-clinical data, favorable safety and pharmacokinetic profiles, and multiple patent applications filed domestically and abroad, the candidate is positioned as a potential best-in-class therapy addressing significant unmet clinical needs in difficult-to-treat hypertension, strengthening CSPC’s innovation credentials and international R&D footprint in cardiovascular medicine.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has had its marketing authorisation application for a fixed-dose Prusogliptin and Metformin extended-release tablet accepted by China’s National Medical Products Administration, marking a significant step in expanding its diabetes treatment portfolio. The combination therapy, built around CSPC’s Class 1 innovative DPP-4 inhibitor prusogliptin and the widely used biguanide metformin, targets adult patients with type 2 diabetes who are inadequately controlled on metformin alone or already on dual therapy, and clinical data show improved and sustained glucose-lowering effects, a lower incidence of hypoglycemia, and a favourable safety profile compared with metformin monotherapy. The once-combination, extended-release formulation is designed to simplify regimens, improve adherence and accommodate patients with mild to moderate renal impairment without dose adjustment, while the company simultaneously advances a triple-therapy candidate combining prusogliptin, dapagliflozin and metformin, reinforcing its positioning in China’s competitive diabetes care market and signalling potential long-term benefits for patients and prescribers if approvals are secured.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to initiate clinical trials of its nintedanib esilate powder for inhalation, the first inhaled formulation cleared for clinical use in China for treating pulmonary fibrosis. Designed as an alternative to the existing oral soft capsule, the inhalation product aims to boost local lung exposure, improve lung function, reduce systemic exposure, and significantly cut gastrointestinal side effects, with preclinical data suggesting similar efficacy at 1/200 of the oral dose and a favorable safety profile; beyond idiopathic pulmonary fibrosis, the candidate may address systemic sclerosis-associated interstitial lung disease and progressive pulmonary fibrosis and is highlighted by the company as a milestone for its inhalation technology platform that could underpin a broader pipeline of inhaled therapies.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has reported that its internally developed GLP-1/GIP receptor dual-biased agonist polypeptide injection, SYH2069, has received approval from China’s National Medical Products Administration to begin clinical trials, complementing an existing U.S. FDA clinical trial approval. Positioned as a potential first-in-class GLP-1/GIP dual-biased agonist in China, SYH2069 is designed to selectively activate the cAMP pathway while limiting receptor internalization and desensitization, aiming to enhance and prolong therapeutic effects; preclinical studies in obese animal models showed superior weight-loss and metabolic benefits versus marketed comparators, with a favorable tolerability profile. The initial clinical indication covers weight management in obese or overweight individuals with at least one weight-related comorbidity, and the drug also shows promise for improving glycemic control in adults with type 2 diabetes, underscoring CSPC’s ambition to strengthen its position in the fast-growing obesity and metabolic disease treatment market.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials for its Prusogliptin, Dapagliflozin and Metformin extended-release tablets, a triple-drug combination therapy for adult patients with type 2 diabetes mellitus whose blood sugar is not adequately controlled with metformin alone. Billed as the world’s first clinically approved combination of these three agents, the product leverages complementary mechanisms of action to target multiple pathophysiological aspects of diabetes, promising effective glycemic control, a favorable safety and tolerability profile, and simplified treatment regimens that may improve patient adherence, while also strengthening CSPC’s presence and pipeline in the competitive metabolic disease market.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of SYH2072, a Class 1 new chemical aldosterone synthase inhibitor tablet for uncontrolled hypertension and primary aldosteronism. The highly selective drug has shown in pre-clinical studies that it can significantly reduce plasma aldosterone and blood pressure without affecting cortisol levels, and with favorable pharmacokinetics and safety, CSPC believes it could become a best-in-class therapy for conditions with substantial unmet clinical need; the company has also filed multiple patent applications in China and overseas, underscoring its push to strengthen its innovative cardiovascular portfolio and competitive position in this high-value segment.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of its Daratumumab Injection, a biosimilar to the multiple myeloma drug Darzalex, for use in adult patients. Developed as a Class 3.3 therapeutic biological product, the antibody drug has shown high similarity to the reference medicine in quality, safety and efficacy in preclinical studies, clearing a key regulatory hurdle that could strengthen CSPC’s position in the domestic oncology biosimilars market if subsequent clinical trials are successful.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has announced a leadership reshuffle effective 19 December 2025, with long-serving executive director Zhang Cuilong stepping down from his roles as vice-chairman, chief executive officer and authorised representative due to work reassignment, while remaining on the board. The company has appointed Cai Lei, currently executive president and head of overseas R&D and pharmaceutical product sales, as vice-chairman, executive director, CEO and authorised representative, and named Wei Qingjei as vice-chairman, executive director and chief operating officer, moves that underscore a tighter alignment of top management with CSPC’s international research and sales strategy and reinforce the influence of the founding Cai family in the group’s governance.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has disclosed an updated list of its board of directors, confirming a large slate of executive and independent non-executive directors led by Chairman Cai Dong Chen and Vice-Chairman and Chief Executive Officer Dr. Cai Lei. The company also detailed the composition of its key board committees, designating roles for audit, nomination and remuneration oversight, with independent directors such as Wang Bo, Chen Chuan, Au Chun Kwok Alan and Li Quan taking on committee chairmanships and memberships, underscoring CSPC’s emphasis on corporate governance and board oversight as it manages its strategic and operational decisions.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of SYH2085, an orally administered Class 1 new chemical drug designed to inhibit the endonuclease activity of the influenza virus PA protein. Targeted for the treatment of uncomplicated influenza A and B in adults and adolescents aged 12 and above, the candidate has shown broad-spectrum antiviral activity, reductions in viral load and flu-like symptoms in pre-clinical models, along with favourable pharmacokinetics and safety, positioning it as a potentially effective new influenza therapy and strengthening CSPC’s anti-infective drug pipeline.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has reported positive topline results from a Phase III, multi-centre, randomised, double-blind equivalence trial of its biosimilar Secukinumab Injection for moderate to severe plaque psoriasis. The study, comparing the company’s fully human IgG1 monoclonal antibody directly with reference drug Cosentyx in Chinese patients, met its primary endpoint of PASI-75 response at Week 12 and demonstrated clinical equivalence in efficacy, along with a favourable and consistent safety profile. The outcome strengthens CSPC’s push into the high-value biologics and biosimilars segment, positioning the group to compete in China’s growing market for IL-17A inhibitors and potentially broadening its future revenue base in autoimmune and inflammatory diseases, subject to regulatory approvals.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has received marketing approval from China’s National Medical Products Administration for a new indication of its irinotecan hydrochloride liposome injection, branded as Duoenyi. This approval allows its use in combination with other drugs for the first-line treatment of metastatic pancreatic cancer, marking a significant milestone as the first domestic approval for such treatment. The decision is based on clinical studies showing improved progression-free survival and a favorable safety profile, reinforcing CSPC’s position in the oncology market and potentially benefiting patients with advanced pancreatic cancer.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group announced that its subsidiary, CSPC Innovation Pharmaceutical Co., Ltd., has submitted an application for an H Share Listing on the Stock Exchange. This move is part of CSPC’s strategy to enhance its market presence and leverage capital markets for growth. The listing is subject to regulatory approvals and market conditions, and the company has cautioned stakeholders about the uncertainties involved.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has received approval from the U.S. FDA to conduct clinical trials for its new product, JMT206, a recombinant fully human anti-ActRIIA/IIB monoclonal antibody. This product, aimed at weight management for individuals with obesity or overweight and at least one weight-related comorbidity, has shown promising results in preclinical studies, indicating high bioavailability and favorable efficacy and safety profiles.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited announced that its second marketing authorization application for Semaglutide Injection, aimed at long-term weight management in overweight adults or obese patients, has been accepted by China’s National Medical Products Administration. This product, developed by its subsidiary CSPC Baike, offers significant clinical advantages in efficacy and safety compared to existing treatments, positioning the company favorably in the competitive pharmaceutical market.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced that its GLP-1/GIP receptor dual-biased agonist polypeptide injection, SYH2069, has received approval from the U.S. FDA to conduct clinical trials in the United States. This product, which is poised to be China’s first of its kind, shows promise in weight management and glycemic control for type 2 diabetes, demonstrating superior efficacy and safety in preclinical studies. The approval marks a significant step for CSPC in enhancing its position in the global pharmaceutical market, particularly in the field of metabolic diseases.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced that its new chemical drug, SYH2056 tablets, a selective 5-HT2A receptor agonist, has received approval from the U.S. FDA to conduct clinical trials for treating major depressive disorder. This development marks a significant step as the drug has shown promising preclinical results, including rapid onset of action and reduced hallucination risks, positioning it as a potential best-in-class antidepressant. The approval highlights the company’s commitment to addressing the limitations of traditional antidepressants and meeting the broad clinical demand for novel therapies.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has announced the approval of its new drug, JMT206, for clinical trials in China. This recombinant fully human anti-ActRIIA/IIB monoclonal antibody is designed to aid in weight management for individuals with obesity or overweight conditions, showing promising efficacy and safety in preclinical studies. The approval marks a significant step in the company’s efforts to enhance its market position in the weight management sector.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$11.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced that its independently developed double-stranded small interfering RNA drug, SYH2061 Injection, has received approval from the U.S. FDA to conduct clinical trials in the United States. This siRNA drug, which targets complement component C5, is designed for the treatment of IgA nephropathy and other complement-mediated diseases. The product has shown promising preclinical results, demonstrating superior pharmacological activity, long-lasting therapeutic effects, and a good safety profile, which could enhance the company’s positioning in the pharmaceutical market.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$11.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has appointed Mr. QU Zhiyong as an Executive Director effective from November 21, 2025. Mr. QU, who has been with the company since 2004 and currently serves as the General Manager of the Hong Kong Head Office Management Centre, will bring his extensive financial expertise to the Board. This strategic appointment is expected to strengthen the company’s leadership and enhance its financial operations, potentially impacting its market positioning positively.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$11.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement provides clarity on the leadership structure and governance, which could impact the company’s strategic direction and reassure stakeholders about its management stability.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$11.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group has announced that its new chemical drug, SYH2056 tablets, a selective 5-HT2A receptor agonist, has received approval for clinical trials in China. This drug, aimed at treating depression, shows promise due to its rapid action, long-lasting effects, and reduced hallucination risk, potentially positioning it as a best-in-class antidepressant. The approval marks a significant step in addressing the limitations of traditional antidepressants and meeting the high clinical demand for novel depression therapies.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$11.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group reported a 12.3% decrease in total revenue and a 7.1% decline in reported profit for the first nine months of 2025 compared to the previous year. The finished drugs segment, which experienced a 17.2% revenue drop, was notably impacted by industry policies like centralized volume-based procurement and drug price adjustments. Despite these challenges, the company saw growth in bulk products and functional foods, indicating a shift in market dynamics.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group announced that its marketing authorization application for Pertuzumab Injection, a treatment for HER2-positive breast cancer, has been accepted by China’s National Medical Products Administration. The product has shown equivalence in efficacy and safety to existing treatments in clinical trials, potentially strengthening CSPC’s position in the oncology market.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced a board meeting scheduled for November 20, 2025, to approve the unaudited third-quarter results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and could impact its market positioning and stakeholder interests.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited announced the resignation of Mr. PAN Weidong as Executive Director and his replacement as the Authorized Representative by Dr. LI Chunlei. This change is part of the company’s ongoing management adjustments, which may influence its strategic direction and operational focus.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited has announced the composition of its Board of Directors, detailing the roles and functions of each member. This announcement is crucial for stakeholders as it outlines the leadership structure and governance, which can impact the company’s strategic direction and operational effectiveness.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
CSPC Pharmaceutical Group Limited announced that its Executive Director, Mr. Pan Weidong, has been penalized by the China Securities Regulatory Commission for insider trading related to a restructuring transaction involving its subsidiary, CSPC Innovation Pharmaceutical Co., Ltd. Despite the penalty, the company maintains that its operations remain unaffected, and the incident is not expected to impact its business negatively.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.